Investigational COVID mucosal vaccine protects against disease and transmission

In animal studies that mimic human exposures, an investigational COVID vaccine designed to be taken orally not only protects the host, but also decreases the airborne spread of the virus to other close contacts.

The study, led by Duke researcher Stephanie N. Langel, Ph.D., demonstrated the potential of a COVID vaccine that works through the mucosal tissue to neutralize the SARS-CoV-2 virus, limiting infections and the spread of active virus in airborne particles.

The findings are published today in the journal Science Translational Medicine.

" Considering most of the world is under-immunized - and this is especially true of children - the possibility that a vaccinated person with a breakthrough infection can spread COVID to unimmunized family or community members poses a public health risk," Langel said. "There would be a substantial benefit to develop vaccines that not only protect against disease, but also reduce transmission to unvaccinated people."

Langel and colleagues - including teams from the vaccine developer, Vaxart, and a clinical research non-profit, Lovelace Biomedical Research Institute - tested a vaccine candidate that uses an adenovirus as a vector to express the spike protein of the SARS-CoV-2 virus. The human vaccine is designed to be taken as a pill.

In studies using hamsters, the vaccine elicited a robust antibody response in blood and the lungs. When the animals were exposed to the SARS-CoV-2 virus at high levels, prompting breakthrough infections, they were less symptomatic than non-vaccinated hamsters, had lower amounts of infectious virus in the nose and lungs. Because of this, they did not shed as much virus through normal airborne exposures.

Unlike vaccines that are injected into the muscle, Langel said, mucosal immunizations increase production of immunoglobulin A (IgA) - the immune system’s first line of defense against pathogens - in the nose and lungs. These mucosal ports of entry are then protected, making it less likely that those who are vaccinated will transmit infectious virus during a sneeze or cough.

"Our data demonstrate that mucosal immunization is a viable strategy to decrease the spread of COVID through airborne transmission," Langel said.

Langel said the study focused on the original SARS-CoV-2 virus, and new studies will be designed to test the vaccine against Omicron variants.

Stephanie N Langel, Susan Johnson, Clarissa I Martinez, Sarah N Tedjakusuma, Nadine Peinovich, Emery G Dora, Philip J Kuehl, Hammad Irshad, Edward G Barrett, Adam Werts, Sean N Tucker.
Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model.
Science Translational Medicine, 2022. doi: 10.1126/scitranslmed.abn6868

Most Popular Now

Findings open way for personalised MS treatment

Currently available therapies to treat multiple sclerosis (MS) lack precision and can lead to serious side effects. Researchers at Karolinska Institutet in Sweden have no...

Pfizer shares top-line results from Phase 2/3 EPIC…

Pfizer Inc. (NYSE: PFE) shared top-line results from the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study evaluating...

Pfizer and Biohaven's VYDURA® (rimegepant) granted…

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorizatio...

A smarter way to develop new drugs

Pharmaceutical companies are using artificial intelligence to streamline the process of discovering new medicines. Machine-learning models can propose new molecules that ...

Cognitive impairment from severe COVID-19 equivale…

Cognitive impairment as a result of severe COVID-19 is similar to that sustained between 50 and 70 years of age and is the equivalent to losing 10 IQ points, say a team o...

Foundation S: Sanofi's new philanthropic spearhead

Sanofi today launches Foundation S - The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partners...

SK bioscience and GSK's adjuvanted COVID-19 vaccin…

SK bioscience and GSK announced submission of a biologics license application for SKYCovione™ a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s...

Investigational COVID mucosal vaccine protects aga…

In animal studies that mimic human exposures, an investigational COVID vaccine designed to be taken orally not only protects the host, but also decreases the airborne spr...

Using AI to analyze large amounts of biological da…

Researchers at the University of Missouri are applying a form of artificial intelligence (AI) - previously used to analyze how National Basketball Association (NBA) playe...

Asthma drug can block crucial SARS-CoV-2 protein

A drug used to treat asthma and allergies can bind to and block a crucial protein produced by the virus SARS-CoV-2, and reduce viral replication in human immune cells, ac...

Recurring brain tumor growth is halted with new dr…

When a non-metastatic brain tumor - a meningioma - recurs after surgery and radiation treatment, a patient is out of options. No drugs are approved for these aggressive t...

Pfizer to acquire Biohaven Pharmaceuticals

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) have entered into a definitive agreement under which Pfizer will acquire Biohaven, t...